Ovarian Cancer Drug Pipeline Analysis Report 2025

Ovarian cancer is the abnormal cell growth in the ovaries or fallopian tubes. These cells multiply quickly and invade the surrounding healthy tissues. According to World Cancer Research Fund International, ovarian cancer is the eighth most common cancer in women across the globe. There are several ovarian cancer emerging drugs under clinical trials intended to develop effective treatment alternatives.

Report Coverage

The Ovarian Cancer Drug Pipeline Report by the publisher gives comprehensive insights for ongoing ovarian cancer clinical trials. It covers various aspects related to the details of ovarian cancer drugs under development. The report includes the analysis of over 100 pipeline drugs and 50+ companies. It will include an analysis based on efficacy and safety measure outcomes published for the trials including their adverse effects on ovarian cancer.

The detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration and ongoing ovarian cancer pipeline development activities are covered. Moreover, ovarian cancer collaborations and commercial assessments are offered, helping stakeholders to make informed decisions.

Ovarian Cancer Drug Pipeline Outlook

Ovarian cancer is when abnormal cells in the ovary start to grow in an uncontrolled manner and eventually lead to tumour formation. These cancer cells can start to grow into the surrounding healthy tissues and spread to other parts of the body as well. According to the American Cancer Society, approximately 19,680 women are expected to be diagnosed with ovarian cancer in 2024, and it is estimated that approximately 12,740 women will die from the condition.

The symptoms of ovarian cancer include abdominal bloating or swelling, discomfort in the pelvic area, feeling full quickly when eating, weight loss, back pain, fatigue, and constipation among others. The ovarian cancer treatment depends on the stage of cancer and the patient's age. The standard treatment includes surgery, chemotherapy, targeted therapy, immunotherapy, and hormone therapy, among others. In 2022, the United States Food and Drug Administration (FDA) provided accelerated ap proval to mirvetuximab soravtansine-gynx (Elahere), the first antibody-drug conjugate for platinum-resistant ovarian cancer.

Multiple NCI-supported research programs are being conducted to develop innovative treatments for ovarian cancer. For instance, the Ovarian Specialized Programs of Research Excellence (SPOREs) promote cancer research. This organization works to improve treatment approaches for ovarian cancer.

Merck is developing an ovarian cancer emerging drug through its flagship drug Keytruda (pembrolizumab), in combination with carboplatin/paclitaxel chemotherapy. The trial is currently under phase III.

The ovarian cancer report assessment covers the pathophysiology and epidemiology of ovarian cancer, developing treatment, and the progress and future aspects of ongoing clinical trials for treatment of ovarian cancer in detail. Genelux Corp is investigating olvimulogene nanivacirepvec, currently under phase III trial. The study evaluates the safety and efficacy of platinum-doublet plus bevacizumab compared to platinum-doublet plus bevacizumab.

Ovarian Cancer - Drug Pipeline Therapeutic Assessment

This section of the report covers the analysis of ovarian cancer drug candidates based on various segmentations such as:

By Phase

The pipeline assessment report covers 50+ drug analyses based on phase.

• Late-Stage Products (Phase III and Phase IV)
• Mid-Stage Products (Phase II)
• Early-Stage Products (Phase I)
• Preclinical and Discovery Stage Products

By Route of Administration

The ovarian cancer therapeutic assessment report covers 50+ drug analyses based on the route of administration.

• Oral
• Parenteral
• Others

Ovarian Cancer - Pipeline Assessment Segmentation, By Phases

The ovarian cancer pipeline analysis covers phase I, phase II, phase III, phase IV, and early phase drugs for ovarian cancer. The coverage includes an in-depth analysis of each drug across these phases. According to analysis, phase II trials cover major share of the total ovarian cancer clinical trials conducted.

AstraZeneca is conducting phase II clinical trial for the drug ola parib to evaluate its efficacy in combination with paclitaxel.

Ovarian Cancer - Pipeline Assessment Segmentation, By Route of Administration

The route of administration categories covered under ovarian cancer pipeline landscape include oral, parenteral and others. The report offers a comparative analysis of the route of administration for each drug in various phases of clinical trials. According to analysis, the parenteral route accounted for a major share of ovarian cancer clinical trials.

Ovarian Cancer Clinical Trials - Competitive Dynamics

The ovarian cancer report insights covers the profile of key companies involved in clinical trials and their drugs under development. Below is the list of a few players involved in clinical trials for ovarian cancer.

• Sanofi
• AstraZeneca
• Seagen Inc.
• Bristol-Myers Squibb
• GlaxoSmithKline
• Lipomedix Pharmaceuticals Inc.
• Astellas Pharma Inc.
• Genentech, Inc.
• Bayer AG
• Others

Ovarian Cancer - Emerging Drugs Profile

This section covers the detailed analysis of each drug under multiple phases including phase I, phase II, phase III, phase IV, and emerging drugs for ovarian cancer. Moreover, it includes product description, trial ID, study type, drug class, mode of administration, and recruitment status among others.

Docetaxel and Cisplatin - Sano fi

Currently, under phase II, the drug is sponsored by Sanofi. The purpose of the study is to assess the safety and efficacy of the first line treatment for advanced epithelial ovarian cancer.

Liposomal Doxorubic in - AstraZeneca

Liposomal Doxorubicin developed by AstraZeneca is currently under phase II. The purpose of the study is to assess the safety and efficiency of two doses of ovarian cancer drug candidate AZD2281 against liposomal doxorubicin.

Paclitaxel - Boehringer Ingelheim

Paclitaxel, developed by Boehringer Ingelheim is presently under phase II. The study is being conducted to evaluate the efficacy and safety of BI 6727 versus single-agent cytotoxic in recurrent third- and fourth-lines platinum-resistant ovarian cancer.

Olaparib, MEDI4736, Bevacizumab - AstraZeneca

The study is assessing the safety and efficacy MEDI4736 in combination with Olaparib vs MEDI4736 in combination with bevacizuma and Olaparib.

Key Questions Answered in the Ovarian Cancer - Pipeline Assessment Report

• What is the current landscape of ovarian cancer pipeline drugs?
• Which companies/institutions are developing ovarian cancer therapeutic drugs?
• How many phase II drugs are currently present in ovarian cancer pipeline drugs?
• Which company is leading the ovarian cancer pipeline development activities?
• What is the current ovarian cancer commercial assessment?
• What are the opportunities and challenges present in the ovarian cancer drug pipeline landscape?
• What is the efficacy and safety profile of ovarian cancer pipeline drugs?
• Which companies/institutions are involved in ovarian cancer collaborations aimed at providing enhanced therapeutic alternatives for patients?
• What are the geographies covered for clinical trials in ovarian cancer?

This product will be delivered within 3-5 business days.